ClinicalTrials.gg
CompletedNCT04214860Updated Mar 17, 2025Results posted

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

A Phase 1 interventional study of APR-246 and Venetoclax in Myeloid Malignancy, sponsored by Aprea Therapeutics. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Aprea Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid malignancies.

Read the detailed description

This study will enroll adult male and female patients of age ≥ 18 years with documented diagnosis of AML, according to WHO classification, and documented TP53 mutation which is not benign or likely benign, who also meet the eligibility requirements of this protocol.

The study will include a safety lead-in dose-finding portion followed by expansion portion. During the safety lead-in portion of the study, two cohorts will independently enroll patients following a 3 + 3 design. Each cohort will enroll up to 6 patients.

The expansion portion will begin once the recommended phase II dose (RP2D) of APR-246 in combination with venetoclax and in combination with venetoclax and azacitidine have been determined in order to assess the antitumor activity of these combinations.

02

Conditions studied

  • Myeloid Malignancy
03

In context

Lead sponsor

Aprea Therapeutics is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and ability to comply with protocol requirements.
  2. Documented diagnosis of AML according to World Health Organization WHO) classification
  3. Adequate organ function as defined by the following laboratory values:

    1. > 30 mL/min
    2. Total serum \< 1.5 ×
    3. (ALT) and aspartate aminotransferase (AST) \< 3 × ULN
  4. Age ≥18 years
  5. At least one TP53 mutation
  6. (ECOG) performance status of 0, 1 or 2
  7. Projected of ≥ 12 weeks.
  8. Negative serum or urine pregnancy test
  9. Females of and males with female partners of childbearing potential must be willing to use an effective form of

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment for TP53-mutant AML (*dependent upon treatment arm assigned).
  2. Known history of or active or active infection.
  3. Any of the following cardiac abnormalities:

    1. Myocardial infarction within six months prior to registration;
    2. Class III or IV heart failure or known (LVEF) \< 40%;
    3. A history of familial long syndrome;
    4. Symptomatic atrial or ventricular arrhythmias
    5. QTcF ≥ 470 msec, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor.
  4. Concomitant for which patients are receiving active therapy
  5. Known active CNS involvement from AML.
  6. Malabsorption syndrome
  7. Pregnancy or lactation.
  8. Active uncontrolled systemic infection (viral, bacterial or fungal).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    APR-246

    APR-246 4.5 g/day

    Drug: APR-246 · Drug: Venetoclax · Drug: Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.

    1. Dose-limiting toxicities (DLTs), classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 5.0).

    Time frame: From baseline until event occures, i.e. through study completion, an average of 1 year

  2. To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.

    2. Frequency of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) related to APR-246 in combination with venetoclax and azacitidine during the trial.

    Time frame: From baseline until event occures, i.e. through study completion, an average of 1 year

07

Results

Posted Feb 21, 2025

Participant flow

Cohort 2 APR-246 + VEN + AZA Safey Lead-In and Expansion data was combined for reporting purposes.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started645
Completed643
Not completed02

Outcome measures

PrimaryTo Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.

1. Dose-limiting toxicities (DLTs), classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 5.0).

Time frame:
From baseline until event occures, i.e. through study completion, an average of 1 year
Reported as:
Number · DLTs
To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.
DLTsCohort 1Cohort 2
To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.00
PrimaryTo Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.

2. Frequency of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) related to APR-246 in combination with venetoclax and azacitidine during the trial.

Time frame:
From baseline until event occures, i.e. through study completion, an average of 1 year
Reported as:
Count of participants · Participants
To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.
ParticipantsCohort 1Cohort 2
To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.532

Adverse events

Collected over 18 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 16/6 (100%)5/6 (83.3%)6/6 (100%)
Cohort 226/43 (60.5%)32/43 (74.4%)43/43 (100%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventCohort 1Cohort 2
SepsisInfections and infestations2/64/43
Febrile NeutropeniaBlood and lymphatic system disorders2/613/43
ParotitisInfections and infestations1/60/43
Respiratory Syncytial Virus InfectionInfections and infestations1/60/43
DiarrheaGastrointestinal disorders1/60/43
Upper Gastrointestinal HemorrhageGastrointestinal disorders1/60/43
Disease progressionGeneral disorders1/61/43
Mucosal InflammationGeneral disorders1/61/43
TachycaridiaCardiac disorders1/60/43
Respiratory FailureRespiratory, thoracic and mediastinal disorders1/60/43
Most frequent other events
Showing 10 of 54
Most frequent other events
EventCohort 1Cohort 2
NasueaGastrointestinal disorders6/627/43
Febrile NeutropeniaBlood and lymphatic system disorders4/619/43
CoughRespiratory, thoracic and mediastinal disorders4/610/43
DiarrheaGastrointestinal disorders3/624/43
VomitingGastrointestinal disorders3/620/43
ConstipationGastrointestinal disorders3/615/43
HypokalemiaMetabolism and nutrition disorders3/614/43
DizzinessNervous system disorders3/613/43
Edema PeripheralGeneral disorders3/613/43
HeadacheNervous system disorders3/69/43

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Total
<=18 years000
Between 18 and 65 years21618
>=65 years42731
Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Median69 (45 to 76)67 (27 to 81)67 (27 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female42024
Male22325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander011
Black or African American101
White33740
More than one race000
Unknown or Not Reported156
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Total
United States64349
08

Study locations

8 sites
  • Yale Cancer Center
    New Haven, Connecticut 06511, United States
  • H. Lee Moffitt CC
    Tampa, Florida 33612, United States
  • Northwestern Medicine
    Chicago, Illinois 60611, United States
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Weill Cornell Cancer Center
    New York, New York 10021, United States
  • Memorial Sloan Kettering CC
    New York, New York 10065, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jan 2022, 25 months.

Results were first posted in Feb 2025, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2019
First posted
Jan 2, 2020
StartActual
Dec 13, 2019
Primary completionActual
Jan 14, 2022
CompletionActual
Jan 14, 2022
Results first posted
Feb 21, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04214860
Lead sponsor
Aprea Therapeutics
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Dec 13, 2019
Primary completion
Jan 14, 2022
Completion
Jan 14, 2022
Results posted
Feb 21, 2025
Last update
Mar 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eprenetapopt

Start the discussion